Seeking Alpha
 

Merck & Co Inc. (MRK)

- NYSE
  • May 20, 2013, 3:37 PM
    Cubist Pharmaceuticals (CBST +11.3%) spikes to session highs. The move appears relates to an apparent Markman ruling on Hospira (HSP +0.7%, which has a generic version of Cubist's drug Cubicin. Seeking Alpha contributor PropThink noted last week that the ruling would likely be a 'clearing event' for the company.
    | May 20, 2013, 3:37 PM | Comment!
  • May 16, 2013, 12:55 PM
    Oncothyreon (ONTY -20.7%) tanks today after presenting data as ASCO that showed Phase III trials of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 didn't meet its primary objective. The trial was conducted by Merck Serono, a division of Merck (MRK -0.7%), under a license agreement with ONTY.
    | May 16, 2013, 12:55 PM | 3 Comments
  • May 15, 2013, 4:01 PM
    Shares of Optimer Pharmaceutical (OPTR +15%) spike into the close on rumors that Cubist Pharmaceutical (CBST -0.5%) lobbed a $1B bid for OPTR prior to the sales process.
    | May 15, 2013, 4:01 PM | Comment!
  • May 14, 2013, 3:34 PM
    Shares of Alimera Sciences (ALIM +22%) churn higher again today, racking up a +55% run over the past three days. The stock has been on the move since announcing in its 10-K that Iluvien had become commercially available in the UK, Germany, France, Spain, Portugal and Austria. Sentiment may also be getting a boost today on a Seeking Alpha article calling the stock an easy double at current levels, and, along with Trius Therapeutics (TSRX +7.7%), could be one of the biggest gainers in 2013.
    | May 14, 2013, 3:34 PM | Comment!
  • May 14, 2013, 11:39 AM
    Shares of Trius Therapeutics (TSRX +5.6%) gain this morning after the company announced late yesterday that it's received a Notice of Allowance from the USPTO on an application related to its tedizolid phosphate patent portfolio. The new application protects a therapeutic combination of the experimental medicine with a currently available antibiotic daptomycin. Together, TSRX claims the medicines can prevent the development of certain strains of staph infection.
    | May 14, 2013, 11:39 AM | Comment!
  • May 13, 2013, 5:09 PM
    Shares of Optimer Pharmaceutical (OPTR +14%) ramped up into the close on reports that AstraZeneca (AZN), Astellas Pharma (ALPMY.PK) and Cubist Pharmaceuticals (CBST) are among the first round bidders for the antibiotic manufacturer. OPTR disclosed almost three months ago that they were working with Centerview Partners and JPMorgan to explore its strategic options, including a potential sale.
    | May 13, 2013, 5:09 PM | Comment!
  • May 7, 2013, 8:05 PM
    Trius Therapeutics (TSRX): Q1 EPS of -$0.38 misses by $0.02. Revenue of $1.73M misses by $3.78M. (PR)
    | May 7, 2013, 8:05 PM | Comment!
  • May 7, 2013, 9:00 AM
    Cubist Pharmaceuticals (CBST) pops 2.56% premarket after the FDA grants Fast Track status (again) to the antibiotic CXA-201 which has now received the designation for all of its indications and is being evaluated in Phase 3 clinicals. (PR)
    | May 7, 2013, 9:00 AM | Comment!
  • May 6, 2013, 1:36 PM
    Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses.
    | May 6, 2013, 1:36 PM | Comment!
  • May 6, 2013, 12:30 PM
    Tesaro (TSRO -0.2%) feels a little heat today from a cautious post in Seeking Alpha. SA author Richard Pearson notes that the stock has more than doubled since its IPO debut last June, largely on enthusiasm for its still far-off cancer drug Niraparib. Over the near term however, the company is facing some significant challenges, particularly for its lead drug Rolapitant, a treatment for nausea and vomiting caused by the effects of chemotherapy. Merck's (MRK -1%) Emend is currently its largest competitor in the space, and will already be generic when Rolapitant comes to market.
    | May 6, 2013, 12:30 PM | Comment!
  • May 3, 2013, 4:09 PM
    The FDA has approved Merck's (MRK -0.2%) Liptruzet drug for treating elevated LDL cholesterol levels in patients with primary or mixed hyperlipidemia. Lipruzet combines two existing anti-cholesterol drugs, ezetimibe and atorvastatin. It'll be available to wholesalers next week. (PR)
    | May 3, 2013, 4:09 PM | 3 Comments
  • May 3, 2013, 11:17 AM
    Cubist Pharmaceuticals (CBST +3.2%) outperforms after UBS starts coverage with a Buy and $61 PT. Jim Cramer recently gave a shout-out to the drug developer, which ticked higher in April following its Q1 miss.
    | May 3, 2013, 11:17 AM | Comment!
  • May 3, 2013, 10:50 AM
    Fitch revises its outlook to Negative from Positive on Merck's (MRK +0.3%) Issuer Default Rating (A+). Apparently, the temptation to fund share buybacks with debt given the favorable rate environment should be weighed against any potential deleterious effects from increased leverage: MRK "intends to use debt issuances … to repurchase $7.5B worth of shares over the next 12 months [but the company] has ample liquidity via cash on hand and operating cash flow … to complete the [buyback] without harm to the credit profile … the financing of the [buyback] program could drive debt leverage to a level that is not reflective of the 'A+' IDR," Fitch says.
    | May 3, 2013, 10:50 AM | 1 Comment
  • May 1, 2013, 7:15 AM
    More on Merck's (MRK) Q1: Earnings beat but revenue misses as patent expirations and unfavorable foreign exchange rates reduce worldwide sales by 9%. The company says it witnessed growth in vaccines, immunology, animal health, and consumer care products during the period. MRK also revises its guidance for the year, saying it now sees non-GAAP EPS of $3.45-3.55. Analysts expect $3.63. Shares -1% premarket. (PR)
    | May 1, 2013, 7:15 AM | 1 Comment
  • May 1, 2013, 7:01 AM
    Merck (MRK): Q1 EPS of $0.85 beats by $0.05. Revenue of $10.67B misses by $0.42B. (PR)
    | May 1, 2013, 7:01 AM | Comment!
  • May 1, 2013, 12:05 AM
    Notable earnings before Wednesday’ s open: AB, ADT, AFAM, AFSI, AGN, AH, AMT, ARW, AVA, CCJ, CHK, CLH, CLX, CMCSA, CVH, CVS, DLPH, DVN, ENR, EXAS, EXC,GRMN, GWR, H, HSP, HUM, ICE, IPGP, IQNT, IRM, JRCC, KCG, KFN, MA, MKL, MRK, NVO, PDCE, PKD, POR, PSX, RDC, RDN, SEE, SPW, TLM, TWX, VG, VIAB, VPHM
    | May 1, 2013, 12:05 AM | Comment!
Visit Seeking Alpha's
MRK vs. ETF Alternatives
Company Description
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.